Ovarian Neoplasms: all 2,757 studies
Page 26 of 28. Open to participants first (735), then studies with results posted, then the rest; newest registration first within each.
- Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian CancerCompletedNCT00466986Phase 2
- MRI in Staging Ovarian Cancer Using MRI Contrast AgentStatus unknownNCT00463996
- Depression and Interleukin-6 Production in Patients With Ovarian Epithelial CancerWithdrawnNCT00460200
- Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian CancerCompletedNCT00452985
- Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal AdenocarcinomasCompletedNCT00443196Phase 2/3
- A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal CancerCompletedNCT00437502Phase 1
- Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer RelapseCompletedNCT00437307Phase 3
- Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal CancerCompletedNCT00436657Phase 1
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedNCT00436254Phase 1
- Assess Cancer in Ovarian Tumors With Biomarkers.CompletedNCT00436189Not applicable
- Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00431054Phase 1
- Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian CarcinomaCompletedNCT00429559Phase 1/2
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian CancerCompletedNCT00428766Phase 1
- Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian CancerCompletedNCT00426257Phase 3
- Pharmacogenomics of Paclitaxel in Ovarian CancerCompletedNCT00415207
- Pharmacogenomics of Paclitaxel in Ovarian CancerCompletedNCT00415181
- Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by SurgeryCompletedNCT00410553Phase 1
- Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.WithdrawnNCT00408967Phase 2
- Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00408655Phase 1
- ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaTerminatedNCT00407407Phase 1
- MITO-6: Capecitabine in Platinum Resistant Ovarian CancerCompletedNCT00403429Phase 2
- MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian CancerCompletedNCT00401674Phase 2
- Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerCompletedNCT00400348Phase 2
- Questionnaire Study for Gynecological Cancer SurvivorsStatus unknownNCT00391664
- Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian CancerCompletedNCT00383279Not applicable
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerCompletedNCT00382811Phase 3
- A Study of ZYC300 Administered With Cyclophosphamide Pre-DosingCompletedNCT00381173Phase 1
- Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian CancerCompletedNCT00368420
- Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma CancerCompletedNCT00352300Phase 1
- Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian CancerTerminatedNCT00350948Phase 3
- Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian CarcinomaStatus unknownNCT00349505Phase 2
- BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00346385Phase 1
- Elizabeth Registry for Low Grade Ovarian CancerCompletedNCT00345709
- Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With GeneticsCompletedNCT00341458
- Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast CancerCompletedNCT00337233Not applicable
- Blood Test for Ovarian Cancer Associated Antibodies (CAAb)Status unknownNCT00327925
- MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian CancerStatus unknownNCT00326456Phase 3
- A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung CancerCompletedNCT00325494Phase 1
- ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian CancerCompletedNCT00325351Phase 2
- Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast CancerCompletedNCT00321633Phase 2
- Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian CancerTerminatedNCT00317434Phase 1
- Risk of Ovarian Cancer in Patients With a Pelvic MassCompletedNCT00315692
- Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal CancerCompletedNCT00314678Phase 2
- Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer TherapyCompletedNCT00312988Phase 3
- Doxil and Gemcitabine in Recurrent Ovarian CancerTerminatedNCT00312650Phase 2
- CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenStatus unknownNCT00305838Phase 2
- Tissue Bank of Biological Specimens From Patients With Gynecologic DiseaseStatus unknownNCT00299481
- Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic CancerCompletedNCT00295945
- CT-2106 for the Second Line Treatment of Ovarian CancerCompletedNCT00291837Phase 2
- Diagnostic Imaging of Lymph Nodes in Gynaecologic OncologyCompletedNCT00288821
- Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube CancerTerminatedNCT00288275
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1
- Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.TerminatedNCT00287482Not applicable
- Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian CancerCompletedNCT00281515Phase 2
- Study of XL999 in Patients With Previously Treated Ovarian CancerTerminatedNCT00277290Phase 2
- Ovarian Screening StudyCompletedNCT00267072
- Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00263822Phase 3
- Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal CancerCompletedNCT00262990Phase 3
- Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian CancerCompletedNCT00261027Phase 2
- Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast CancerCompletedNCT00253539Phase 2
- Clinical Benefit of Topoisomerase DownregulationCompletedNCT00250094Phase 1
- Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian MassesStatus unknownNCT00248820Not applicable
- DOXIL for Consolidation Therapy in Ovarian Cancer.CompletedNCT00248248Phase 2
- Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian CancerCompletedNCT00246688Phase 2
- Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for ApoptosisCompletedNCT00243685Phase 2/3
- Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)CompletedNCT00239980Phase 2
- Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic MassStatus unknownNCT00238342Not applicable
- Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) CancersCompletedNCT00231855Phase 2
- Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IVCompletedNCT00231075Phase 2
- Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2
- Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu VaccineCompletedNCT00228358Phase 1
- Treatment of Newly Diagnosed Ovarian Cancer With AntioxidantsCompletedNCT00228319Phase 1/2
- Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00217568Phase 2
- Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00217529Phase 1/2
- Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based ChemotherapyCompletedNCT00216645Phase 2
- Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian CancerCompletedNCT00216112Phase 2
- Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal CancerCompletedNCT00214058Phase 2
- Weekly Topotecan Therapy in Patients With Ovarian CancerTerminatedNCT00194935Phase 2
- Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00193297Phase 2
- A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.CompletedNCT00191607Phase 3
- Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian CancerTerminatedNCT00189579Phase 2
- Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early RelapseCompletedNCT00189566Phase 2
- Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late RelapseCompletedNCT00189553Phase 3
- Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic TumoursCompletedNCT00189410Phase 2
- Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or PeritoneumTerminatedNCT00189371Phase 3
- A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based TherapyCompletedNCT00189358Phase 2
- Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer PatientsCompletedNCT00189345Phase 2
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerCompletedNCT00181688Phase 2
- Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaTerminatedNCT00179725Phase 1/2
- Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal CarcinomaCompletedNCT00179712Phase 1/2
- Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian CancersStatus unknownNCT00178802Phase 2
- The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer PatientsStatus unknownNCT00173394
- Preference Study With Elderly Patients Recurrent Ovarian CancerCompletedNCT00170690Phase 3
- Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian CancerCompletedNCT00170677Phase 2
- Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian CancerCompletedNCT00170664Phase 2
- Evaluation of Vasopressin in the Vessels of Ovarian NeoplasmsCompletedNCT00160472Not applicable
- The Development of Human Immunologic Assays Specific to Folate Receptor AntigenStatus unknownNCT00155935Not applicable
- Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian CancerStatus unknownNCT00155896
- Mesothelin as a New Tumor Marker for Ovarian CancerStatus unknownNCT00155740
- IGFBP-3 in Ovarian Cancer InvasionStatus unknownNCT00154986Not applicable